Metastasectomy for visceral and skeletal oligorecurrent prostate cancer

Battaglia, Antonino; Devos, Gaëtan; Decaestecker, Karel; Witters, Manuel; Moris, Lisa; Broeck, Thomas Van den; Berghen, Charlien; Everaerts, Wouter; Albersen, Maarten; Tsaturyan, Arman; Meerleer, Gert De; Poppel, Hein Van; Goffin, Karolien; Ost, Piet; Tosco, Lorenzo; Joniau, Steven

doi:10.1007/s00345-019-02716-8

Cited by 20 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is inconsistent with the results of our analysis, which may also be due to the short follow-up time in the included studies. However, Battaglia et al further conducted metastatic surgical treatment in 17 oligometastatic prostate cancer patients and observed a 4-year OS of 66%, with three patients dying of prostate cancer [ 49 ]. In addition, Sheng et al performed statistical analyses of 43 patients and found that cryosurgery prolonged patient PFS by reducing CTC counts [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis

Mao

Yang³

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Background Whether cytoreductive prostatectomy (CRP) should be performed in patients with oligometastatic prostate cancer (OPC) remains controversial. The goal of this systematic meta-analysis was to assess the efficacy of CRP as a treatment for OPC. Methods This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. Data sources included publications in the PubMed, Embase, the Cochrane Library, EBSCO, and Web of Science (SCI) databases as of May 2022. Eligible articles included prospective studies comparing the efficacy of CRP to a lack of CRP in patients with OPC. Results In total, 10 publications incorporating 888 patients were analyzed. Tumor-reducing prostatectomy was found to have no significant effect on long-term or short-term OS [OR = 2.26, 95% CI (0.97, 5.28), P = 0.06] and [OR = 1.73, 95% CI (0.83, 3.58), P = 0.14], but it significantly improved patient long-term or short-term CSS [OR = 1.77, 95% CI (1.01, 310), P = 0.04] and [OR = 2.71, 95% CI (1.72, 4.29), P < 0.0001] and PFS [OR = 1.93, 95% CI (1.25, 2.97), P = 0.003]. Conclusion These results suggest that cytoreductive prostatectomy can confer survival benefits to OPC patients. Trial registration INPLASY protocol 202260017 https://doi.org/10.37766/inplasy2022.6.0017.

show abstract

Section: Discussionmentioning

confidence: 99%

Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis

Mao

Yang³

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…These procedures were performed by experts of the affected organ (e.g., lobectomy by a thoracic surgeon, partial hepatectomy by a hepatobiliary surgeon) [ 31 ].…”

Section: Methodsmentioning

confidence: 99%

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy

Devos

Berghen

Eecke

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Several retrospective and a few prospective studies have shown that metastasis-directed therapy (MDT) could delay clinical progression and postpone the initiation of systemic treatment in oligorecurrent prostate cancer (PCa) patients. However, these endpoints are strongly influenced by variables such as concomitant use of androgen deprivation therapy (ADT) and follow-up imaging protocols. The aim of this manuscript was to assess palliative ADT- and metastatic castration-resistant prostate cancer (mCRPC)-free survival as long-term oncological outcomes in oligorecurrent PCa treated by MDT. We retrospectively identified consecutive post-prostatectomy oligorecurrent PCa patients treated by MDT (salvage lymphadenectomy, radiotherapy, or metastasectomy) at our tertiary referral center. Patients were eligible for inclusion if they developed recurrence following radical prostatectomy, had ≤5 metastatic lesions on imaging and had a serum testosterone >50 ng/dL or a testosterone suppression therapy-free interval of >2 years prior to the first MDT as an assumption of recovered serum testosterone (if no testosterone measurement available). Patients with castration-resistant or synchronous oligometastatic PCa at the time of first MDT were excluded. Repeated MDTs were allowed, as well as a period of concomitant ADT. Kaplan–Meier analyses were performed to assess palliative ADT-free and mCRPC-free survival. We identified 191 eligible patients who underwent MDT. Median follow-up from first MDT until last follow-up or death was 45 months (IQR 27–70; mean 51 months). Estimated median palliative-ADT free survival was 66 months (95% CI 58–164) and estimated median mCRPC-free survival was not reached (mean 117 months, 95% CI 103–132). In total, 314 MDTs were performed and 25 patients (13%) received ≥3 MDTs. This study demonstrated that (repeated) MDT is feasible and holds promise in terms of palliative ADT-free and mCRPC-free survival for patients with oligorecurrent PCa. However, these findings should be confirmed in prospective randomized controlled trials.

show abstract

“…included 17 patients with visceral or skeletal oligometastatic (≤3 lesions) recurrent PCa after primary treatment and carried out surgical excision of visceral or skeletal lesions. 94 The authors found that after repeated MDS sessions and a median follow-up of 43 months, 35% of the patients remained radiographically disease-free at last follow-up. 94 Of note, 77% of the patients did not receive adjuvant or salvage ADT and 4-year OS was 66%.…”

Section: Metastasis-directed Surgerymentioning

confidence: 96%

“… 94 The authors found that after repeated MDS sessions and a median follow-up of 43 months, 35% of the patients remained radiographically disease-free at last follow-up. 94 Of note, 77% of the patients did not receive adjuvant or salvage ADT and 4-year OS was 66%. 94 One of the largest retrospective studies on the role of MDT assessed CRPC- and ADT-FS in patients who developed oligorecurrent mPCa (≤5 metastatic lesions on imaging) following RPx (±adjuvant or salvage RT) with a serum testosterone level >50 ng/dl.…”

Section: Metastasis-directed Surgerymentioning

confidence: 96%

“… 94 Of note, 77% of the patients did not receive adjuvant or salvage ADT and 4-year OS was 66%. 94 One of the largest retrospective studies on the role of MDT assessed CRPC- and ADT-FS in patients who developed oligorecurrent mPCa (≤5 metastatic lesions on imaging) following RPx (±adjuvant or salvage RT) with a serum testosterone level >50 ng/dl. 95 Participants were treated with MDRT or MDS (RT, SLND, or metastasectomy) and 25 patients (13%) received ≥3 MDTs.…”

Section: Metastasis-directed Surgerymentioning

confidence: 99%

See 1 more Smart Citation